Meeting
2011 ASCO Annual Meeting
Combination of lenalidomide with R-CHOP (R2CHOP) as an initial therapy for aggressive B-cell lymphomas: A phase I/II study.
Authors
G. S. Nowakowski
Mayo Clinic, Rochester, MN
G. S. Nowakowski , C. B. Reeder , B. LaPlant , T. M. Habermann , C. Rivera , W. R. Macon , D. J. Inwards , I. N. M. Micallef , P. B. Johnston , L. F. Porrata , S. M. Ansell , T. E. Witzig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT00670358
Citation
J Clin Oncol 29: 2011 (suppl; abstr 8015)
Abstract #
8015
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Activity of the immunologic doublet of lenalidomide plus obinutuzumab in relapsed follicular lymphoma: Results of a phase I/II study.
First Author: Nathan Hale Fowler
Poster
2022 ASCO Annual Meeting
Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
First Author: Hua-Jay Jeffery Cherng
Poster
2021 ASCO Annual Meeting
Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).
First Author: Jia Ruan
Poster
2020 ASCO Virtual Scientific Program
Phase I/II study of R-ICE (rituximab-ifosfamide-carboplatin-etoposide) with lenalidomide (R2-ICE) in patients with first-relapse/primary refractory diffuse large B-cell lymphoma (DLBCL) in academic and community cancer research united (ACCRU) network.
First Author: Francis Guerra-Bauman